Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

Benzinga · 1d ago
Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $38 to $31.